Sichuan Biokin Pharmaceutical

688506.SSPre-clinical

Chengdu, ChinaFounded 2009biokin.com.cn

Sichuan Biokin Pharmaceutical Co., Ltd. is a leading Chinese biopharmaceutical company established to develop and commercialize innovative biological medicines with a focus on monoclonal antibodies and biosimilars. Listed on the Shanghai Stock Exchange STAR Market under ticker 688506.SS, the company has built comprehensive capabilities spanning drug discovery, development, manufacturing, and commercialization. With a current market valuation of approximately $16.3 billion, Biokin represents one of China's prominent biotech success stories in the biologics space.

Market Cap

$16.3B

Founded

2009

Focus

Biotech

688506.SS · Stock Price

USD 271.48+239.43 (+747.05%)

Historical price data

AI Company Overview

Technology Platform

Comprehensive biologics platform focused on monoclonal antibody discovery, development, and manufacturing, with capabilities spanning both innovative biologics and biosimilar development.

Funding History

IPOUndisclosedUndisclosedJun 15, 2020

Opportunities

Significant growth opportunities in China's rapidly expanding biologics market, driven by increasing healthcare spending, favorable regulatory environment, and growing demand for innovative therapies.

International expansion potential as capabilities mature.

Risk Factors

Key risks include competitive pressure in the biologics space, regulatory and clinical development risks, manufacturing challenges, and potential market access pressures.

Currency and geopolitical factors may impact international expansion plans.

Competitive Landscape

Operates in a competitive Chinese biotech market against both domestic players and international pharmaceutical companies. Differentiation likely comes from local market knowledge, regulatory expertise, and cost-effective manufacturing capabilities.

Publications